Inhibition of KMT9 catalytic activity results in reduced cellular levels of H4K12me1, down-regulation of KMT9 target genes involved in cell cycle regulation and, in consequence, in the suppression of prostate tumour cell growth. This evidence concerns the gene HEMK2 and prostate neoplasm.